Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM) (TREX)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Extended-release naltrexone (XR-NTX, VIVITROL) is an FDA-approved medication with efficacy in treating alcohol dependence and prevention of relapse to opioid dependence. It has shown promise in reducing relapse to amphetamine use among amphetamine-dependent, yet currently amphetamine-abstinent heterosexuals. The investigators will expand upon this promising work to determine whether monthly intramuscular injections of naltrexone will reduce methamphetamine (meth) use among actively using, meth-dependent men who have sex with men (MSM) in this double-blind randomized controlled trial of extended-release naltrexone versus placebo. The investigators will focus on MSM because of the disproportionate and intertwining epidemics of meth use and HIV in this population.
| Condition | Intervention | Phase |
|---|---|---|
|
Amphetamine-Related Disorders |
Drug: extended-release naltrexone Drug: Placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Extended-Release Naltrexone (XR-NTX, VIVITROL) for the Treatment of Actively-Using Methamphetamine-Dependent Men Who Have Sex With Men |
- urine meth positivity [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]proportion of meth-metabolite positive urines by study arm, measured weekly from week 0 through week 12
- reduction in sexual risk behavior [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]reduction in meth-associated sexual risk behavior as measured by: numbers of male anal sex partners, serodiscordant unprotected anal sex partners, and numbers of sex partners with whom meth was used, by study arm
- percentage of total expected injections administered [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]acceptability of extended-release naltrexone vs placebo, as measured by the percentage of total expected injections administered, by study arm
- rates of adverse events [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]rates of adverse events will be compared by study arm
| Estimated Enrollment: | 100 |
| Study Start Date: | September 2012 |
| Estimated Study Completion Date: | March 2015 |
| Estimated Primary Completion Date: | December 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: naltrexone |
Drug: extended-release naltrexone
3 monthly intramuscular injections of naltrexone 380 mg
Other Names:
|
| Placebo Comparator: placebo |
Drug: Placebo
3 monthly intramuscular injections of placebo, matched to naltrexone 380 mg
|
Detailed Description:
The investigators will enroll 100 sexually active, meth-dependent MSM who will be randomized 1:1 to receive monthly injections of extended-release naltrexone (n=50) or placebo (n=50) for 12 weeks at weeks 0, 4, and 8. Study participants will be seen weekly at our site at the HIV Prevention Section of the San Francisco Department of Public Health, where they will provide urine for drug testing and participate in substance use counseling. All participants will receive HIV risk-reduction counseling. Behavior will be assessed using standardized measures via audio computer-assisted self-interview (ACASI).
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Inclusion criteria:
- born male; or born female and does not identify as female
- reports having anal sex with men in the prior six months while under the influence of meth;
- diagnosed with meth dependence as determined by SCID;
- interested in stopping or reducing meth use;
- at least one meth-positive urine during screening and run-in period;
- no current acute illnesses requiring prolonged medical care;
- no chronic illnesses that are likely to progress clinically during trial participation;
- able and willing to provide informed consent and adhere to visit schedule;
- age 18-65 years;
- baseline CBC, total protein, albumin, glucose, alkaline phosphatase, creatinine, BUN, total bilirubin, and electrolytes without clinically significant abnormalities as determined by investigator in conjunction with symptoms, physical exam, and medical history.
Exclusion criteria:
- any psychiatric condition (e.g. current depression with suicidal ideation or schizophrenia) that would preclude safe participation in the protocol;
- known intolerance and/or hypersensitivity to naltrexone, carboxymethylcellulose, or polylactide-co-polymers (PLG) or any other components of the diluents;
- current use of or dependence on any opioids; a known medical condition which currently requires or is likely to require opioid analgesics; or positive opioid urine screening tests
- diagnosed with current alcohol dependence as determined by the SCID;
- current CD4 count < 200 cells/mm3;
- moderate or severe liver disease (AST and/or ALT > 3 times upper limit of normal);
- moderately or severely impaired renal function (eGFR < 50 mL/min);
- thrombocytopenia or other coagulation disorder
- currently participating in another research study;
- pending legal proceedings with high risk for incarceration during the time of planned study participation;
- any condition that, in the principal investigator's judgment, interferes with safe study participation or adherence to study procedures.
Contacts and Locations| Contact: Deirdre Santos, RN, MSN, FNP | 415-703-7273 | deirdre.santos@sfdph.org |
| United States, California | |
| HIV Bridge, San Francisco Department of Public Health | Recruiting |
| San Francisco, California, United States, 94102 | |
| Principal Investigator: | Steven L. Batki, MD | Chief, Substance Abuse Programs, San Francisco VA Medical Center |
| Principal Investigator: | Susan Buchbinder, MD | Bridge HIV, San Francisco Department of Public Health |
More Information
No publications provided
| Responsible Party: | University of California, San Francisco |
| ClinicalTrials.gov Identifier: | NCT01449565 History of Changes |
| Other Study ID Numbers: | R01DA031678, R01DA031678 |
| Study First Received: | October 4, 2011 |
| Last Updated: | April 18, 2013 |
| Health Authority: | United States: Federal Government United States: Food and Drug Administration United States: Institutional Review Board |
Keywords provided by University of California, San Francisco:
|
methamphetamine high-risk sexual behavior HIV prevention |
Additional relevant MeSH terms:
|
Amphetamine-Related Disorders Substance-Related Disorders Mental Disorders Naltrexone Methamphetamine Narcotic Antagonists Physiological Effects of Drugs Pharmacologic Actions Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents |
Therapeutic Uses Sympathomimetics Autonomic Agents Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Central Nervous System Stimulants Adrenergic Agents Adrenergic Uptake Inhibitors Neurotransmitter Uptake Inhibitors Dopamine Uptake Inhibitors |
ClinicalTrials.gov processed this record on June 13, 2013